Artículos

Search


Current issue: Volume 71 • Number 4 • May 2018

free

Something is changing in the diagnosis and treatment of non-muscle invasive bladder cancers (NMIBC)

Alejandro Sousa Escandón.

Arch. Esp. Urol. 2018; 71 (4): 325-327

+ info

Future advances in the endovesical treatment of NMIBC.

Miguel Unda-Urzaiz

Arch. Esp. Urol. 2018; 71 (4): 328-331

+ info

BCG and bladder cancer: Past, present and future.

Álvaro Sánchez González, Óscar Rodríguez Faba, Lucía Mosquera, Laia Sabiote, Alberto Breda y Joa, et al

Arch. Esp. Urol. 2018; 71 (4): 332-341

+ info

BCG therapy in NMIBC: How much and for how long?.

Annelisse Ashton, Venkata Ramana Murthy Kusuma, Jeremy Crew y A. Hugh Mostafid.

Arch. Esp. Urol. 2018; 71 (4): 342-348 Keywords: B

+ info

Therapetic options after BCG failure.

Andrea Sánchez Vázquez, José Gregorio Pereira Arias, Mikel Gamarra Quintanilla, Felipe Urdane, et al

Arch. Esp. Urol. 2018; 71 (4): 349-357 Keywords: N

+ info

Mechanism of action of intravesical BCG. Biological bases and clinical applicability.

Joaquín A. Carballido y María Rodríguez Monsalve.

Arch. Esp. Urol. 2018; 71 (4): 358-375

+ info

Immediate post TURBT MMC instillation.

José Luis Domínguez-Escrig.

Arch. Esp. Urol. 2018; 71 (4): 376-383

+ info

New endovesical chemotherapy drugs and application vehicles.

Emilio Rios González 1 y Luis Martínez-Piñeiro2

Arch. Esp. Urol. 2018; 71 (4): 384-392

+ info

Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.

Jonathan Barclay, Joanne Creswell y Juan León.

Arch. Esp. Urol. 2018; 71 (4): 393-399

+ info

Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.

Jacqueline J.M.J.H. Coenen†, F. Johannes P. van Valenberg, Tom J.H. Arends y J. Alfred W, et al

Arch. Esp. Urol. 2018; 71 (4): 400-408

+ info

EMDA with MMC. Critical review.

Eduardo Solsona.

Arch. Esp. Urol. 2018; 71 (4): 409-416

+ info

Mitomycin C HIVEC. Update and results in high risk patients.

Félix Guerrero-Ramos, Daniel Castellano-Gauna, Esther García-Rojo, José Manuel Duarte-Ojeda, , et al

Arch. Esp. Urol. 2018; 71 (4): 417-425

+ info

Analysis of tolerance and security of chemo hyperthermia with Mitomycin C for the treatment of non-muscle invasive bladder cancer

Juan León-Mata, José Luis Domínguez, Joan Palou Redorta, Daniel Sousa González, María Álvarez Casa, et al

Arch. Esp. Urol. 2018; 71 (4): 426-437

+ info

Neoadjuvant chemohyperthermia: Our experience after 10 years.

Alejandro Sousa Escandón, Juan León Mata, Daniel Sousa González, María Álvarez Casal, Silvia Rodr, et al

Arch. Esp. Urol. 2018; 71 (4): 438-446

+ info

Heat-targeted drug delivery: A promising approach for organsparing treatment of bladder cancer. THERMODOX®

Alireza Aminsharifi, Steven C. Brousell, Andrew Chang, Juan León y Brant A. Inman.

Arch. Esp. Urol. 2018; 71 (4): 447-452

+ info

Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.

Venancio Chantada-Abal, Cristina Chantada-Tirado, Leticia Lamas-Díaz, Francisco Caramés- Ma, et al

Arch. Esp. Urol. 2018; 71 (4): 453-457 Keywords: B

+ info

Copyright © 2015 | Valid support N°12/08-W-CM | ISSN-ONLINE: 1576-8260 |